ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA accepts Acadia’s application for dementia drug Nuplazid
July 22, 2020The US Food and Drug Administration (FDA) has accepted Acadia Pharmaceuticals’ supplemental new drug application (sNDA) for an antipsychotic drug, named Nuplazid (pimavanserin) to treat hallucinations and delusions in dementia patients. -
Acadia Pharmaceuticals Plunges Following Report that Links Nuplazid to High Number of Deaths
April 10, 2018Acadia Pharmaceuticals' stock fell by more than 18% in premarket trading, triggering concerns about some deaths and adverse events in the company's Parkinson's drug, Nuplazid.
Pharma Sources Insight January 2025
